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KEY POINTS 42 
Question 43 
What are the long-term mesh removal rates following mid-urethral mesh sling insertion among 44 
women with stress urinary incontinence? 45 
Findings 46 
In this retrospective cohort study that included 95,057 women who underwent mid-urethral mesh 47 
sling insertion for stress urinary incontinence, the rate of sling removal was 3.3% at 9 years. 48 
Meaning 49 
These findings may inform decision making when choosing treatment for stress urinary incontinence. 50 
  51 
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ABSTRACT 52 
Importance 53 
There is concern about outcomes of mid-urethral mesh sling insertion for women with stress urinary 54 
incontinence. However, there is little evidence on long-term outcomes. 55 
Objective 56 
To examine long-term mesh removal and reoperation rates in women who had a mid-urethral mesh 57 
sling insertion for stress urinary incontinence. 58 
Design and participants 59 
Population based retrospective cohort study including 95,057 women aged 18 or older who had a 60 
first-ever mid-urethral mesh sling insertion for SUI in the National Health Service hospitals in 61 
England between 1 April 2006 and 31 December 2015. Women were followed up until 1 April 2016.   62 
Exposures 63 
Patient and hospital factors and retropubic or transobturator mesh sling insertions. 64 
Main Outcomes 65 
Primary outcome was the risk of mid-urethral mesh sling removal (partial or total) and secondary 66 
outcomes were reoperation for stress urinary incontinence, and any reoperation including mesh 67 
removal, calculated with death as competing risk. A multivariable Fine-Gray model was used to 68 
calculate subdistribution hazard rations (sdHR) as estimates of relative risk. 69 
Results 70 
The study population consisted of 95,057 women (median age, 51 years, IQR, 44-61 years) with first 71 
mid-urethral mesh sling insertion, including 60,194 with retropubic insertion and 34,863 with 72 
transobturator insertion. Median follow-up time was 5.5 years (IQR 3.2-7.5 years). Rate of mid-73 
urethral mesh sling removal was 1.4% (95% CI 1.3%-1.4%) at one year, 2.8% (2.7%-2.9%) at five 74 
years and 3.3% (3.2%-3.4%) at nine years. Risk of removal declined with age. The 9-year removal 75 
risk after transobturator insertion (2.7%; 2.5%-2.9%) was lower risk than after retropubic insertion 76 
(3.6%; 3.5%-3.8%; sdHR 0.72, 0.62-0.84). Rate of reoperation for stress urinary incontinence was 77 
1.3% (95% CI: 1.3%-1.4%) at one year, 3.5% (95% CI: 3.4%-3.6%) at five years, and 4.5% (95% CI: 78 
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4.4%-4.6%) at nine years. Rate of any reoperation including mesh removal was 2.7% (2.6%-2.8%) at 79 
one year, 5.5% (5.4%-5.7%) at five years and 6.9% (6.7%-7.1%) at nine years. 80 
Conclusions and Relevance: 81 
Among women undergoing mid-urethral mesh sling insertion, the rate of mesh sling removal at 9 82 
years was estimated as 3.3%. These findings may guide women and their surgeons when making 83 
decisions about surgical treatment of stress urinary incontinence. 84 
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INTRODUCTION 85 
Stress urinary incontinence (SUI) affects approximately one in three women over the age of 18 at 86 
some point in their lives, with substantial effects on quality of life.1,2 It has recently been estimated 87 
that a woman who is currently 18 years old has a 14% chance to undergo surgery for SUI during her 88 
lifetime, based on claims data covering a period between 2002 and 2011 in the USA.3 Synthetic mid-89 
urethral mesh sling insertion (MUS) was developed as a less invasive alternative to major abdominal 90 
surgery for SUI and its use is supported by professional bodies.4-7 In 2010, based on industry 91 
estimates, approximately 250,000 MUS operations for SUI were performed in the USA.8   92 
 93 
There is concern about problems that some women experience following MUS insertion, including 94 
pain, dyspareunia, persistent urinary incontinence, and exposure or erosion.9,10 However, there is little 95 
randomized clinical trial evidence on these longer term outcomes.1 96 
 97 
Recent evidence from routine practice in Scotland (1997-2016) and England (2007-2015) suggests 98 
about 10% of women who had MUS inserted were admitted for a complication (combining those 99 
related to heamorrahage, infection, pain and mesh removal) within five years, with 5% undergoing 100 
further continence surgery.11,12 Reviews of urogynecologic mesh conducted by the Food and Drug 101 
Administration in the USA, the Scottish government and the English National Health Service13-15 102 
concluded that complications are ‘not rare’ and that there is insufficient evidence on longer term 103 
outcomes.8,14 The continued use of MUS for SUI was recommended but only with improved 104 
communication to patients of the risks and benefits of mesh and non-mesh procedures.  105 
 106 
This study aimed to examine the long-term mesh removal and reoperation rates in women who had a 107 
MUS insertion for stress urinary incontinence. The study used administrative hospital data to identify 108 
all women who had a first MUS insertion for SUI in English National Health Service (NHS) hospitals 109 
between 2006 and 2016, and followed them up for up to 10 years. 110 
 111 
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 112 
METHODS 113 
The use of the Hospital Episode Statistics (HES) data for the purpose of national clinical audits and 114 
and evaluations of care delivered by the NHS was approved by the Confidentiality Advisory Group of 115 
the NHS Health Research Authority (15/CAG/0148). 116 
 117 
Study design 118 
This study is a national population-based retrospective cohort study using HES data. HES contains 119 
records of all inpatient admissions to NHS hospitals in England16, with data on patient demographics 120 
(age, sex and ethnicity), the admission (date of admission and discharge) and clinical information. 121 
Diagnostic information is coded using the International Classification of Diseases, 10th revision 122 
(ICD-10).17 Operative procedures are described using the UK Office for Population Censuses and 123 
Surveys classification, 4th revision (OPCS-4).18 It has been demonstrated that the accuracy of HES 124 
data is sufficiently robust to support their use for research and managerial decision-making.19 125 
 126 
All women aged 18 years or older who underwent a MUS insertion procedure for SUI for the first 127 
time between 1 April 2006 and 31 December 2015 were identified. SUI was defined by the ICD-10 128 
code N39.3. Mesh sling insertions were defined by the OPCS-4 codes M53.3 (introduction of tension-129 
free vaginal tape) and M53.6 (introduction of transobturator tape). These codes to identify retropubic 130 
and transobturator mesh sling insertions were introduced in April 2006, the start of the study period, 131 
and formed the coding standards in HES for the duration of the study. The procedure was considered 132 
to be a first-ever mesh sling insertion (‘initial’ procedure) if there was no record of a mesh sling 133 
procedure in the preceding three years. Follow-up was from date of initial procedure to date of a mesh 134 
sling removal, reoperation, or to the end of the follow-up period (31 March 2016), whichever was 135 
earlier. As a consequence, the minimum follow-up period was three months and the maximum 10 136 
years. 137 
 138 
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Outcomes 139 
The primary outcome, ‘mesh sling removal following the initial insertion’, was defined as total or 140 
partial removal of retropubic mesh sling insertion (OPCS-4 codes M53.4 and M53.5) or removal of a 141 
transobturator insertion (OPCS-4 code M53.7). Further definitions of codes can be found in eTable 1. 142 
Due to coding limitations, it was not possible to distinguish partial and total removals following 143 
transobturator insertions. The secondary outcomes, ‘reoperation for SUI’ was defined as a further SUI 144 
procedure (OPCS-4 codes in eTable 1), and ‘any reoperation’ included both mesh removals and 145 
reoperation for SUI. The OPCS -4 codes used to identify the outcomes (MUS removal and 146 
reoperation for SUI) were used in HES throughout the study period. 147 
 148 
Patient factors 149 
Data on patient factors were extracted from HES: age at initial procedure date, Index of Multiple 150 
Deprivation (IMD), an area-based measure of economic deprivation based on postcode of residence at 151 
the time of the initial procedure20, grouped into quintiles according to the national distribution, ethnic 152 
background (white, Asian/Asian-British, black/black-British, or other based on ethnicity information 153 
specified by the patients), number of comorbidities (defined using the RCS Charlson Comorbidity 154 
Index21, grouped as 0 or 1 or more), route of mesh sling insertion (retropubic or transobturator), 155 
previous non-mesh SUI procedures in the preceding thre years and concurrent prolapse operations 156 
(defined using codes listed in eTable 2) in the same episode of care as the initial MUS insertion for 157 
SUI. Ethnicity is considered in this study because previous studies have suggested that there are 158 
variations in care for women with SUI from different ethnic and socio-economic backgrounds.22 In 159 
hospital settings, guidelines state that ethnicity should be self-reported by patients wherever possible, 160 
with assistance from relatives, interpreters or advocates as required.23 The groupings of the 2001 161 
Census are used.  162 
 163 
Organisational factors 164 
Two organisational factors related the hospital where the initial procedure was carried out were also 165 
extracted from HES: the number of MUS insertions performed at the year of initial operation  (annual 166 
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‘volume’; OPCS-4 codes: M53.6 or M53.3); and the hospitals’ status as a specialist urogynecology 167 
unit according to whether they were accredited by the British Society of Urogynaecology unit at any 168 
point in time during the inclusion period.24 169 
 170 
Statistical analyses 171 
The cumulative incidence function was used to estimate removal and reoperation risk as a function of 172 
time from the initial procedure to first mesh sling removal or first reoperation with death as a 173 
competing event and patients reaching the end of the follow-up period as censoring event.25 Because 174 
the primary interest of this study was in the absolute risk of mesh sling removal and reoperation to 175 
support medical decision, we used a multivariable Fine-Gray model to estimate subdistribution hazard 176 
ratios (sdHR) to assess the association between patient and organisational factors and the risk of 177 
removal or reoperation and or mesh removal, with robust standard errors to account for within-178 
hospital homogeneity in outcomes.26 A sdHR of 1 implies no association, a sdHR < 1 a decrease of 179 
the risk compared to the reference category, and a sdHR > 1 an increase. We tested whether the 180 
assumption of proportional subhazards was met by inspecting the cumulative incidence as a function 181 
of time for the categories of each of the patient and organisational factors. We also reran the 182 
competing risk regression analysis, including time interactions separately for each of the patient and 183 
organisational factors. 184 
 185 
Multiple imputation was used to deal with missing values for ethnicity with statistical coefficients 186 
obtained from 10 imputed datasets, pooled using Rubin’s rules.27 Estimates are reported with 95% 187 
confidence intervals (CI). Wald tests were used to test whether the association of patient and 188 
organisational factors with removal or reoperation risks were statistically significant. All reported p 189 
values were 2-sided and 0.05 was used as the significance level. All statistical calculations were 190 
performed using Stata 14.28 To assess whether the results were robust to coding changes introduced in 191 
2006, regression analyses were repeated in two separate sensitivity analyses, first, starting the study 192 
period one year later, on 1 April 2007 (rather than 2006), and second, including the previous coding 193 
standards to identify procedures. 194 
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 195 
RESULTS 196 
112,152 women were identified as having undergone a first MUS insertion (Figure 1) between 1 April 197 
2006 and 31 December 2015. 17,095 patients were excluded because they were not resident in 198 
England, did not have a diagnostic code indicating SUI, or had been treated as private patients (many 199 
NHS hospitals have private wards where private patients may use the services of the hospital 200 
provider)29. Of the included 95,057 women, 60,194 (63.3%) had a retropubic and 34,863 (36.7%) a 201 
transobturator insertion and they were all followed up until the end of the follow-up period. Median 202 
follow up time was 5.5 years for women who did not have a mesh sling removal and who were alive 203 
at the end of follow-up (interquartile range 3.2 and 7.5 years). The median follow-up times for women 204 
who had retropubic and transobturator insertion were 5.4 years (IQR 3.1-7.6 years) and 5.6 years 205 
(IQR 3.4-7.5 years) respectively. The women’s median age was 51 years (IQR 44-61 years), and 206 
19.8% had one or more comorbidities. 18.1% had a concurrent prolapse operation in the same episode 207 
as their MUS insertion (Table 1). 208 
 209 
Mesh sling removal 210 
Mesh sling was removed in 1.4% (95% CI: 1.3%-1.4%) of the women at one year, in 2.7% (95% CI: 211 
2.6%-2.8%) at five years, and in 3.3% (95% CI: 3.2%-3.4%) at nine years after the initial insertion, 212 
accounting for the competing risk of death (Table 1 and Figure 2). The risk of removal was higher (at 213 
all time points) in women who had a retropubic insertion than in those who had a transobturator 214 
insertion (3.6% compared to 2.7% at nine years after insertion, Table 1, Figure 3). This difference 215 
remained after adjusting for other risk factors (sdHR for transobturator insertion: 0.72, 95% CI: 0.62-216 
0.84). The risk of mesh sling removal decreased with age (4.4% for women 18-39 years compared to 217 
2.1% for women over 70 years of age at nine years after insertion, sdHR 0.46, 95% CI: 0.38-0.56) 218 
(Table 1). We did not find an indication that the assumption of proportional subhazards was violated, 219 
except for the route of mesh sling insertion variable. While a visual inspection of Figure 3 does not 220 
suggest violation of the assumption, the competing risk regression with a time varying component for 221 
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route of mesh sling insertion show that the difference between cumulative incidence for removals 222 
following retropubic and transobturator insertions declines over time.  223 
 224 
Reoperation for SUI 225 
Risk of reoperation for SUI was 1.3% (95% CI: 1.3%-1.4%) of the women at one year, in 3.5% (95% 226 
CI: 3.4%-3.6%) at five years, and in 4.5% (95% CI: 4.4%-4.6%) at nine years after the initial 227 
insertion, accounting for the competing risk of death (Table 2 and Figure 2). The risk of reoperation 228 
was higher (at all time points) in women who had transobturator insertion than in those who had a 229 
retropubic insertion (5.3% compared to 4.1%  at nine years after insertion, Table 2, Figure 3). This 230 
difference remained after adjusting for other risk factors (sdHR for transobturator insertion: 1.31, 95% 231 
CI: 1.14-1.51). Higher risk of reoperation for SUI was associated with having undergone a non-mesh 232 
continence procedure prior to the initial MUS insertion in this study (8.1% for women who had a 233 
bulking injection and 4.5% for women who did not, sdHR 1.74, 95% CI: 1.32-2,29; 11.1% for women 234 
who had another non-mesh SUI procedures and 4.5% for women did not, sdHR 2.60, 95% CI: 1.85-235 
3.65) (Table 2).  We did not find an indication that the assumption of proportional subhazards was 236 
violated. 237 
 238 
Any reoperation (mesh removal and/or reoperation for SUI) 239 
The risk of any reoperation (mesh removal and/or reoperation for SUI) following the initial MUS 240 
insertion was 2.6% at 1 year (95% CI: 2.5%-2.7%), 5.5% at five years (95% CI: 5.4%-5.7%) and 241 
6.9% at nine years (95% CI: 6.7%-7.1%, Table 3). The risk of any reoperation was not statistically 242 
significantly different after retropubic or transobturator insertion (Table 3) Asian/Asian-British had a 243 
lower risk of reoperation than women from a white ethnic background (5.4% compared to 7.0% at 244 
nine years after insertion, sdHR 0.75, 95% CI: 0.59 -0.96). Higher risk of any reoperation was 245 
associated with having undergone a non-mesh continence procedure prior to the initial MUS insertion 246 
in this study (10.3% for women who had a bulking injection and 6.9% for women who did not, sdHR 247 
1.55, 95% CI: 1.20-1.99; 14.5% for women who had another non-mesh SUI procedures and 6.9% for 248 
women did not, sdHR 2.29, 95% CI: 1.66-3.14) (Table 3).  We did not find an indication that the 249 
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assumption of proportional subhazards was violated, except for the route of mesh sling insertion 250 
variable. The competing risk regression with a time varying component for route of mesh sling 251 
insertion show that the difference between cumulative incidence for any reoperations following 252 
retropubic and transobturator insertions declines over time. 253 
 254 
Of the 95,057 women in the cohort, 5,328 (5.6%) had at least one reoperation (for mesh removal 255 
and/or reoperation for SUI) (eTable 3). As their first reoperation, 2,276 (2.4%) women had a sling 256 
removal operation, 1,957 (2.2%) had a repeat mesh sling insertion, and 1,075 (1.1%) had a non-mesh 257 
SUI operation. The risk of sling removal as the first reoperation following the initial MUS insertion 258 
was 1.3% at 1 year (95% CI: 1.2%-1.3%), 2.4% at five years (95% CI: 2.3%-2.5%) and 2.9% at nine 259 
years (95% CI: 2.8%-3.1%. Amongst the 1,957 women who had a repeat mesh sling insertions, 1592 260 
(81.3%) were without sling removal as compared with 143 (7.3%) with concurrent sling removal. 261 
Remaining 244 (125%) of repeat mesh sling insertions were recorded with an additional unspecified 262 
revisional procedure code (one of 12 non-specific OPCS-4 codes, eTable 1). The risk of repeat sling 263 
insertion as the first reoperation for SUI following the initial MUS insertion was 0.9% at 1 year (95% 264 
CI: 0.8%-0.9%), 2.1% at five years (95% CI: 2.0%-2.2%) and 2.7% at nine years (95% CI: 2.5%-265 
2.8%). The risk of a non-mesh SUI operation as the first reoperation for SUI was 0.4% at 1 year (95% 266 
CI: 0.4%-0.5%), 1.2% at five years (95% CI: 1.1%-1.2%) and 1.5% at nine years (95% CI: 1.4%-267 
1.6% ) (Table 3). 268 
 269 
Types of subsequent operations by initial route of insertion are provided in eTable 4. Of the 95,057 270 
women in the cohort, 1832 (1.9%) had only removal operations and 1681 (1.8%) had only insertion 271 
operations in the follow-up period. 0.9% of women had multiple types of operations (removals, 272 
insertion and non-mesh SUI operations).   273 
 274 
By April 2016, 490 women who had initially received a retropubic mesh sling had undergone a total 275 
removal operation during the study period. Of these 490 women, 56 (11.4%) had a repeat MUS 276 
insertion following the total removal operation. Therefore, only 434 (0.7%) of the 60,194 women who 277 
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had an initial retropubic insertion had their mesh sling fully removed without any subsequent insertion 278 
(eTable 4). Presented as the cumulative incidence according to time from the initial procedure, the 279 
total removal rates of a retropubic mesh sling without a reinsertion were 0.4% (95% CI: 0.3%-0.4%) 280 
at one year, 0.7% (95% CI: 0.7%- 0.8%) at five years and 0.9% (95% CI: 0.8%-1.0%) at nine years 281 
(Figure 4). 282 
 283 
DISCUSSION 284 
Within nine years of an MUS insertion, 3.3% of women had a removal procedure, 4.5% had a 285 
reoperation for SUI and 6.9% had any reoperation (mesh removal and/or reoperation for SUI). 286 
Removal rates were lower following transobturator insertions than following retropubic insertions, 287 
and rates of reoperation for SUI were lower following retropubic insertions than following 288 
transobturator insertions. Risks of removal and any reoperation (mesh removal and/or reoperation for 289 
SUI) were higher among young women and among women from a white ethnic background. These 290 
findings, showing lower removal rates after tranobturator insertions, are in line with earlier studies 291 
from Scotland and England.11,12 However, these studies did not provide cumulative incidence results 292 
for removal and reoperation (mesh removal and/or reoperation for SUI) as a function of time after 293 
reoperation11 or include admissions for complication without surgery12, which complicates a direct 294 
comparison.  295 
 296 
In routine practice in the English NHS, risks of MUS removal were 2.7% at five years and 3.3% at 297 
nine years, however, 99.3% of women who had an initial retropubic MUS insertion between 1 April 298 
2006 and 31 December 2015 still had a full or partial MUS in situ at the end of the study period. This 299 
can be understood because most removals were partial removals and many women had another mesh 300 
sling inserted (eTable 4 and Figure 5). Due to coding limitations, the proportion of women who had at 301 
least a partial MUS in situ after a sling insertion and removal could only be estimated for women who 302 
had a retropubic insertion, but it is unlikely that these results would be markedly different for women 303 
who had a transobturator insertion.  304 
 305 
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The present results demonstrate that removal and reoperation risks were associated with the insertion 306 
route and patient factors. The risk of a removal was about 30% lower if the mesh sling had been 307 
inserted via the transobturator route, which may be explained by the removal of transobturator sling 308 
being a more complicated procedure. However, the risk of any reoperation, also including partial or 309 
total mesh sling removals, was not associated with the route of insertion which, albeit indirectly, 310 
indicates that risk of a reoperation for SUI is higher in women who had a transobturator insertion. A 311 
Cochrane review also found that the risk of reoperation is higher after a transobturator mesh sling 312 
insertion, but this came from four small trials including only 695 women.1 313 
 314 
The risk of mesh removal or any reoperation (mesh removal and/or reoperation for SUI) was 315 
considerably lower in older patients and in women from non-white ethnic backgrounds, but an 316 
association with socio-economic deprivation was not observed. These findings demonstrate that 317 
removal and reoperation risks may be associated with women’s background. However, it is not 318 
possible to disentangle potential explanations for these difference in risks, which range from higher 319 
morbidity to differences in severity of the underlying condition that led to surgery as well as to how 320 
women perceived possible issues related to having a mesh sling inserted and their choices about 321 
seeking further clinical advice and treatment. 322 
 323 
The use of mesh sling as a treatment for female SUI is rapidly decreasing in the UK with a reduction 324 
by about 50% between 2008 and 2017.30 This highlights a change in patient choice and surgical 325 
practice which is likely to reflect concerns about longer-term complications, outcomes and risk of 326 
further surgery after MUS insertion.  327 
 328 
To our knowledge, this is the largest study of outcomes following MUS insertions for SUI in almost 329 
100,000 women. The administrative hospital dataset had near-100% coverage of patients treated in the 330 
English NHS, reducing the risk of selection bias. Furthermore, it is likely that at least 90% of all 331 
incontinence procedures carried out in England are provided by the NHS, given that the total annual 332 
spending on private health care in England is about 5% of the total annual spending on the NHS.31 333 
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 334 
Limitations 335 
This study has several limitations. First, some relevant clinical and patient characteristics (e.g. 336 
smoking, severity of incontinence, obesity) and the reasons why removal or reoperations were carried 337 
out were not available. 338 
 339 
Second, this study only reported on women who underwent a surgical intervention after the mesh 340 
sling insertion.32 The advantage of this approach is that within administrative hospital data the 341 
accuracy for procedural coding is greater than for diagnostic coding.19 In this way, this study avoided 342 
overestimation of the complication rate or inconsistency in coding, problems that are recognised when 343 
diagnosis codes are being used for this purpose or when outpatient visit are being used as an indicator 344 
of further healthcare use.33 However, this approach did not capture any problems that did not lead to 345 
surgical treatment. 346 
 347 
Third, new procedure codes for retropubic and transobturator mesh sling insertions were introduced in 348 
April 2006, the start of the study period. Prior to this, these procedures were recorded along with other 349 
non-classified procedures. Some inaccuracies may have resulted where certain units continued to use 350 
the old coding standard in the first year of the study period. However, the findings were robust to 351 
sensitivity analyses starting the study period one year later and to including the previous coding 352 
standards. 353 
 354 
Fourth, three times as many partial removals as total removals were performed following retropubic 355 
mesh sling insertions. This study was unable to explore the type of the removal following 356 
transobturator insertions because removal type was not captured for these insertions. Therefore, the 357 
effect of the more challenging operative procedure to remove transobturator slings cannot be 358 
commented on. 359 
 360 
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Fifth, coding limitations mean that this study cannot provide insight into why MUS slings were 361 
removed. The most common diagnostic code recorded in removals episodes is T83 (Complications of 362 
genitourinary prosthetic devices, implants and grafts) which is unable to capture the commonly 363 
reported problems following MUS insertion such as mesh exposure, pain, voiding dysfunction and 364 
other diagnoses. The finding that mesh removal is more common after retropubic MUS insertions may 365 
suggest that voiding problems are a leading reason for removals, although patient-reported data is 366 
required to provide insight into the reasons for MUS removal.  367 
 368 
 369 
Conclusions 370 
Among women undergoing mid-urethral mesh sling insertion, the rate of mesh sling removal at 9 371 
years was estimated as 3.3%. These findings may guide women and their surgeons when making 372 
decisions about surgical treatment of stress urinary incontinence. 373 
  374 
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Table 1: Risk of mesh sling removal following initial mesh sling insertion 495 
    Risk of removal1 (%)    
    Number (%) 
 
1-year 5-year 9-year 
 
Subdistribution 
hazard ratio 
(95% CI)
2
 
P-value
3
 
(95% CI) (95% CI) (95% CI) 
All: crude risk (n/N, %)   1275/90215 (1.4) 1508/52715 (2.9) 240/6981 (3.4)    
All: adjusted risk  95057 (100) 
 
1.4 (1.3, 1.4) 2.7 (2.6, 2.8) 3.3 (3.2, 3.4) 
   
Age at initial surgery (years) 
        
  18-39 10292 (10.8) 
 
2.0 (1.7, 2.2) 3.6 (3.2, 4.0) 4.4 (3.9, 4.9) 
 
Reference <0.001 
  40-49 33094 (34.8) 
 
1.5 (1.4, 1.6) 2.9 (2.8, 3.1) 3.7 (3.4, 4.0) 
 
0.83 (0.74, 0.93) 
 
  50-59 24664 (26.0) 
 
1.4 (1.2, 1.5) 2.8 (2.6, 3.1) 3.4 (3.1, 3.6) 
 
0.77 (0.68, 0.87) 
 
  60-69 16877 (17.8) 
 
1.0 (0.8, 1.1) 2.1 (1.9, 2.3) 2.5 (2.2, 2.8) 
 
0.56 (0.48, 0.66) 
 
  70+ 10130 (10.7) 
 
0.9 (0.8, 1.1) 1.7 (1.5, 2.0) 2.1 (1.7, 2.5) 
 
0.46 (0.38, 0.56) 
 
Index of multiple deprivation 
        
  1 Most deprived quintile 16136 (17.0) 
 
1.3 (1.1, 1.5) 2.7 (2.4, 2.9) 3.2 (2.9, 3.5) 
 
Reference 0.12 
  2 18277 (19.2) 
 
1.5 (1.3, 1.7) 2.9 (2.7, 3.2) 3.5 (3.2, 3.8) 
 
1.12 (0.97, 1.30) 
 
  3 20468 (21.5) 
 
1.3 (1.1, 1.5) 2.5 (2.3, 2.8) 3.0 (2.7, 3.3) 
 
0.96 (0.83, 1.12) 
 
  4 20779 (21.9) 
 
1.3 (1.1, 1.4) 2.6 (2.4, 2.9) 3.2 (2.9, 3.6) 
 
1.01 (0.87, 1.18) 
 
  5 Least deprived quintile 19397 (20.4) 
 
1.5 (1.3, 1.7) 2.8 (2.5, 3) 3.5 (3.2, 3.9) 
 
1.08 (0.92, 1.25) 
 
Ethnic background4 
        
  White 83451 (95.8) 
 
1.4 (1.3, 1.5) 2.7 (2.6, 2.8) 3.3 (3.2, 3.4) 
 
Reference 0.08 
  Asian/Asian-British 2049 (2.4) 
 
0.9 (0.5, 1.3) 2.1 (1.6, 2.9) 2.9 (2.0, 4.1) 
 
0.73 (0.51, 1.05) 
 
  Black/black-British 576 (0.6) 
 
1.7 (0.9, 3.0) 2.3 (1.3, 3.7) 2.3 (1.3, 3.7) 
 
0.71 (0.42, 1.19) 
 
  Other 1057 (1.2) 
 
0.9 (0.5, 1.6) 1.9 (1.2, 2.9) 2.8 (1.6, 4.5) 
 
0.73 (0.49, 1.09) 
 
 Missing (n=7924, 8.3%)         
Route of mesh sling insertion 
        
  Retropubic 60194 (63.3) 
 
1.6 (1.5, 1.7) 3.0 (2.9, 3.2) 3.6 (3.5, 3.8) 
 
Reference <0.001 
  Transobturator 34863 (36.7) 
 
0.9 (0.8, 1.0) 2.2 (2.0, 2.3) 2.7 (2.4, 2.9) 
 
0.72 (0.62, 0.84) 
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Table 1 (continued)   Risk of removal
1
    
    Number (%) 
 
1-year 
(95% CI) 
5-year 
(95% CI) 
9-year 
(95% CI)  
Subdistribution 
hazard ratio 
(95% CI)
2
 
P-value
3
 
Comorbidities5 
        
  None 76252 (80.2) 
 
1.4 (1.3, 1.5) 2.7 (2.6, 2.8) 3.3 (3.2, 3.5) 
 
Reference 0.37 
  1 or more 18805 (19.8) 
 
1.3 (1.1, 1.5) 2.7 (2.4, 2.9) 3.0 (2.7, 3.3) 
 
1.05 (0.94, 1.17) 
 
Previous bulking injection 
        
  No 94349 (99.2) 
 
1.4 (1.3, 1.5) 2.7 (2.6, 2.8) 3.3 (3.1, 3.4) 
 
Reference 0.36 
  Yes 709 (0.8) 
 
0.7 (0.3, 1.6) 3.0 (1.9, 4.6) 3.3 (2.1, 5.0) 
 
1.21 (0.80, 1.83) 
 
Previous other stress urinary 
incontinence procedure         
  No 94710 (99.6) 
 
1.4 (1.3, 1.4) 2.7 (2.6, 2.8) 3.3 (3.1, 3.4) 
 
Reference 0.13 
  Yes 347 (0.4) 
 
2.6 (1.3, 4.7) 4.2 (2.4, 6.8) 4.2 (2.4, 6.8) 
 
1.50 (0.89, 2.52) 
 
Concurrent prolapse repair 
        
  No 77932 (82.0) 
 
1.4 (1.3, 1.4) 2.7 (2.6, 2.8) 3.3 (3.1, 3.4) 
 
Reference 0.09 
  Repair with mesh 817 (0.9) 
 
1.7 (1.0, 2.8) 3.4 (2.3, 4.9) 3.9 (2.6, 5.6) 
 
1.43 (0.98, 2.08) 
 
  Repair without mesh 16308 (17.2) 
 
1.4 (1.2, 1.6) 2.7 (2.5, 3.0) 3.3 (2.9, 3.6) 
 
1.07 (0.93, 1.22) 
 
Specialist urogynecology unit 
        
  No 75695 (79.6) 
 
1.3 (1.2, 1.4) 2.6 (2.5, 2.7) 3.1 (3.0, 3.3) 
 
Reference 0.17 
  Yes 19362 (20.4) 
 
1.7 (1.6, 1.9) 3.2 (2.9, 3.4) 3.8 (3.5, 4.2) 
 
1.17 (0.94, 1.47) 
 
Annual volume of mesh sling 
insertions         
  < 60 28939 (30.3) 
 
1.3 (1.2, 1.4) 2.5 (2.3, 2.7) 3.0 (2.8, 3.3) 
 
Reference 0.21 
  60-119 44228 (46.5) 
 
1.4 (1.3, 1.5) 2.7 (2.6, 2.9) 3.4 (3.2, 3.6) 
 
1.07 (0.92, 1.24) 
 
  ≥120 21990 (23.1) 
 
1.5 (1.3, 1.6) 2.8 (2.6, 3.0) 3.4 (3.1, 3.7) 
 
1.02 (0.82, 1.28) 
 
 496 
1Cumulative incidence function and corresponding 95% confidence interval (95% CI) according to time after initial insertion.  497 
2 Sub-hazard ratios calculated with competing risks regression model (Fine & Gray34) adjusted for all patient and hospital factors in table.  498 
3P value obtained from Wald test 499 
4Ethnicity percentages calculated for non-missing data 500 
5Number of comorbidities derived from Royal College of Surgeons Charlson Comorbidity Index 501 
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 502 
Table 2: Risk of reoperation for stress urinary incontinence following initial mesh sling insertion 503 
 504 
     
 
Risk of reoperation for stress urinary incontinence
1
 (%) 
   
    Number (%) 
 
1-year 
(95% CI) 
5-year 
(95% CI) 
9-year 
(95% CI)  
Subdistribution  
hazard ratio 
(95%CI)
2
 
P-value
3
 
All: crude risk (n/N, %)   1252/90215 (1.4) 2087/52715 (3.9) 391/6981 (5.6)    
All: adjusted risk 95057 (100) 
 
1.3 (1.3, 1.4) 3.5 (3.4, 3.6) 4.5 (4.3, 4.7) 
   
Age at initial surgery (years)  
       
  18-39 10292 (10.8) 
 
1.1 (1.0, 1.3) 3.3 (3.1, 3.5) 4.5 (4.2, 4.8) 
 
Reference 0.29 
  40-49 33094 (34.8) 
 
1.3 (1.1, 1.4) 3.4 (3.2, 3.7) 4.2 (3.9, 4.6) 
 
0.91 (0.80, 1.03) 
 
  50-59 24664 (26.0) 
 
1.6 (1.4, 1.8) 3.7 (3.4, 4.1) 4.6 (4.2, 5.0) 
 
0.92 (0.81, 1.05) 
 
  60-69 16877 (17.8) 
 
1.7 (1.4, 1.9) 3.8 (3.4, 4.2) 4.3 (3.9, 4.8) 
 
1.00 (0.86, 1.16) 
 
  70+ 10130 (10.7) 
 
1.1 (1.0, 1.3) 3.3 (3.1, 3.5) 4.5 (4.2, 4.8) 
 
0.99 (0.83, 1.18) 
 
Index of multiple deprivation  
       
  1 Most deprived quintile 16136 (17.0) 
 
1.3 (1.1, 1.5) 3.5 (3.2, 3.8) 4.2 (3.9, 4.6) 
 
Reference 
 
  2 18277 (19.2) 
 
1.4 (1.2, 1.5) 3.7 (3.4, 4.0) 4.9 (4.5, 5.4) 
 
1.08 (0.96, 1.23) 
 
  3 20468 (21.5) 
 
1.3 (1.2, 1.5) 3.5 (3.2, 3.7) 4.3 (4.0, 4.7) 
 
0.99 (0.87, 1.13) 
 
  4 20779 (21.9) 
 
1.4 (1.2, 1.5) 3.8 (3.5, 4.1) 4.9 (4.5, 5.3) 
 
1.09 (0.94, 1.26) 
 
  5 Least deprived quintile 19397 (20.4) 
 
1.3 (1.1, 1.4) 3.1 (2.8, 3.3) 4.1 (3.8, 4.5) 
 
0.92 (0.78, 1.09) 
 
Ethnic background4  
       
  White 83451 (95.8) 
 
1.4 (1.3, 1.4) 3.5 (3.4, 3.7) 4.6 (4.4, 4.8) 
 
Reference 
 
  Asian/Asian-British 2049 (2.4) 
 
0.8 (0.5, 1.2) 2.5 (1.9, 3.3) 3.1 (2.3, 4.0) 
 
0.74 (0.54, 1.01) 
 
  Black/black-British 576 (0.6) 
 
1.0 (0.4, 2.1) 3.1 (1.8, 4.9) 3.4 (2.0, 5.3) 
 
0.71 (0.46, 1.10) 
 
  Other 1057 (1.2) 
 
0.8 (0.4, 1.5) 2.4 (1.5, 3.5) 2.8 (1.7, 4.2) 
 
0.70 (0.45, 1.07) 
 
 Missing (n=7924, 8.3%)         
Route of mesh sling insertion  
       
  retropubic 60194 (63.3) 
 
1.2 (1.1, 1.3) 3.1 (3.0, 3.3) 4.1 (3.8, 4.3) 
 
Reference <0.001 
  transobturator 34863 (36.7) 
 
1.5 (1.4, 1.6) 4.1 (3.9, 4.4) 5.3 (5.0, 5.7) 
 
1.31 (1.14, 1.51) 
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 Table 2 (continued)  
 
Risk of reoperation for stress urinary incontinence
1
 (%) 
   
    Number (%) 
 
1-year 
(95% CI) 
5-year 
(95% CI) 
9-year 
(95% CI)  
Subdistribution 
hazard ratio 
(95%CI)
2
 
P-value
3
 
Comorbidities5  
       
  None 76252 (80.2) 
 
1.3 (1.2, 1.4) 3.4 (3.3, 3.6) 4.5 (4.3, 4.7) 
 
Reference 0.35 
  1 or more 18805 (19.8) 
 
1.5 (1.3, 1.7) 3.8 (3.5, 4.1) 4.4 (4.0, 4.8) 
 
1.04 (0.95, 1.14) 
 
 
Previous bulking injection 
 
       
  No 94349 (99.2) 
 
1.3 (1.2, 1.4) 3.5 (3.3, 3.6) 4.5 (4.3, 4.7) 
 
Reference <0.001 
  Yes 709 (0.8) 
 
2.9 (1.8, 4.3) 6.9 (5.1, 9.1) 8.1 (5.9, 10.6) 
 
1.74 (1.32, 2.29) 
 
Previous other stress urinary incontinence 
procedure 
 
       
  No 94710 (99.6) 
 
1.3 (1.2, 1.4) 3.5 (3.3, 3.6) 4.5 (4.3, 4.7) 
 
Reference <0.001 
  Yes 347 (0.4) 
 
4.9 (3.0, 7.6) 9.1 (6.3, 12.6) 11.1 (7.8, 15.1) 
 
2.60 (1.85, 3.65) 
 
Concurrent prolapse repair  
       
  No 77932 (82.0) 
 
1.4 (1.3, 1.4) 3.6 (3.5, 3.7) 4.7 (4.5, 4.9) 
 
Reference 0.001 
  Repair with mesh 817 (0.9) 
 
2.8 (1.9, 4.2) 4.9 (3.5, 6.6) 6.2 (3.9, 9.3) 
 
1.32 (0.94, 1.84) 
 
  Repair without mesh 16308 (17.2) 
 
1.1 (0.9, 1.3) 3.0 (2.7, 3.3) 3.7 (3.3, 4.1) 
 
0.80 (0.69, 0.93) 
 
Specialist urogynecology unit  
       
  No 75695 (79.6) 
 
1.3 (1.2, 1.4) 3.5 (3.4, 3.6) 4.5 (4.3, 4.8) 
 
Reference 0.84 
  Yes 19362 (20.4) 
 
1.4 (1.2, 1.5) 3.5 (3.2, 3.8) 4.4 (4.0, 4.8) 
 
1.02 (0.81, 1.29) 
 
Annual volume of mesh sling insertions  
       
  < 60 28939 (30.3) 
 
1.2 (1.1, 1.4) 3.4 (3.2, 3.6) 4.4 (4.1, 4.8) 
 
Reference 0.37 
  60-119 44228 (46.5) 
 
1.4 (1.3, 1.5) 3.6 (3.5, 3.8) 4.7 (4.4, 4.9) 
 
1.09 (0.96, 1.24) 
 
  ≥120 21990 (23.1) 
 
1.3 (1.1, 1.4) 3.4 (3.1, 3.6) 4.3 (4.0, 4.7) 
 
1.03 (0.83, 1.28) 
 
 505 
1Cumulative incidence function and corresponding 95% confidence interval (95% CI) according to time after initial insertion.  506 
2 Sub-hazard ratios calculated with competing risks regression model (Fine & Gray34) adjusted for all patient and hospital factors in table.  507 
3P value obtained from Wald test 508 
4Ethnicity percentages calculated for non-missing data 509 
5Number of comorbidities derived from Royal College of Surgeons Charlson Comorbidity Index510 
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Table 3: Risk of mesh removal or reoperation for stress urinary incontinence following initial mesh sling insertion 511 
 512 
    
 
 Risk of any reoperation
1
 (%) 
   
    Number (%)  
1-year 
(95% CI) 
5-year 
(95% CI) 
9-year 
(95% CI)  
Subdistribution  
hazard ratio 
(95%CI)
2
 
P-value
3
 
All: crude risk (n/N, %)   2415//90215 (2.7) 3216/52715 (6.1) 553/6981 (7.9)    
All: adjusted risk  
 
 2.6 (2.5, 2.7) 5.5 (5.4, 5.7) 6.9 (6.7, 7.1) 
   
Age at initial surgery (years) 
 
 
      
  18-39 10292 (10.8)  3.1 (2.8, 3.4) 6.3 (5.8, 6.9) 8.3 (7.6, 9.2) 
 
Reference 0.01 
  40-49 33094 (34.8)  2.5 (2.3, 2.7) 5.4 (5.2, 5.7) 7.1 (6.7, 7.4) 
 
0.86 (0.79, 0.94) 
 
  50-59 24664 (26.0)  2.5 (2.3, 2.7) 5.6 (5.3, 5.9) 6.8 (6.4, 7.2) 
 
0.86 (0.78, 0.95) 
 
  60-69 16877 (17.8)  2.5 (2.3, 2.7) 5.4 (5.1, 5.8) 6.6 (6.1, 7.1) 
 
0.83 (0.74, 0.94) 
 
  70+ 10130 (10.7)  2.5 (2.2, 2.9) 5.3 (4.9, 5.8) 6.1 (5.5, 6.7) 
 
0.79 (0.68, 0.91) 
 
Index of multiple deprivation 
 
 
      
  1 Most deprived quintile 16136 (17.0)  2.5 (2.2, 2.7) 5.5 (5.1, 5.9) 6.6 (6.1, 7.1) 
 
Reference 0.13 
  2 18277 (19.2)  2.7 (2.4, 2.9) 5.8 (5.5, 6.2) 7.3 (6.8, 7.8) 
 
1.08 (0.97, 1.20) 
 
  3 20468 (21.5)  2.5 (2.3, 2.7) 5.4 (5.0, 5.7) 6.5 (6.1, 7.0) 
 
0.98 (0.88, 1.08) 
 
  4 20779 (21.9)  2.6 (2.3, 2.8) 5.7 (5.3, 6.0) 7.2 (6.8, 7.7) 
 
1.05 (0.94, 1.17) 
 
  5 Least deprived quintile 19397 (20.4)  2.6 (2.4, 2.9) 5.3 (5.0, 5.7) 6.9 (6.4, 7.4) 
 
1.00 (0.88, 1.13) 
 
Ethnic background4 
 
 
      
  White 83451 (95.8)  2.6 (2.5, 2.7) 5.6 (5.4, 5.8) 7.0 (6.8, 7.2) 
 
Reference 0.01 
  Asian/Asian-British 2049 (2.4)  1.5 (1.1, 2.1) 4.3 (3.5, 5.3) 5.4 (4.2, 6.8) 
 
0.75 (0.59, 0.96) 
 
  Black/black-British 576 (0.6)  2.7 (1.6, 4.2) 5.0 (3.4, 7.1) 5.0 (3.4, 7.1) 
 
0.73 (0.51, 1.05) 
 
  Other 1057 (1.2)  1.7 (1.1, 2.6) 3.9 (2.8, 5.2) 5.2 (3.6, 7.3) 
 
0.74 (0.54, 1.01) 
 
 Missing (n=7924, 8.3%)         
Route of mesh sling insertion 
 
 
      
  retropubic 60194 (63.3)  2.7 (2.6, 2.9) 5.5 (5.3, 5.7) 6.8 (6.5, 7.0) 
 
Reference 0.61 
  transobturator 34863 (36.7)  2.3 (2.1, 2.4) 5.7 (5.4, 5.9) 7.2 (6.8, 7.5) 
 
1.03 (0.92, 1.16) 
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 Table 3 (continued) 
 
 Risk of reoperation
1
 (%) 
   
    Number (%)  
1-year 
(95% CI) 
5-year 
(95% CI) 
9-year 
(95% CI)  
Subdistribution 
hazard ratio 
(95%CI)
2
 
P-value
3
 
Comorbidities5 
 
 
      
  None 76252 (80.2)  2.5 (2.4, 2.6) 5.5 (5.3, 5.7) 7.0 (6.7, 7.2) 
 
Reference 0.22 
  1 or more 18805 (19.8)  2.7 (2.5, 2.9) 5.8 (5.4, 6.1) 6.6 (6.2, 7.1) 
 
1.05 (0.97, 1.13) 
 
 
Previous bulking injection  
 
      
  No 94349 (99.2)  2.6 (2.5, 2.7) 5.5 (5.4, 5.7) 6.9 (6.7, 7.1) 
 
Reference 0.001 
  Yes 709 (0.8)  3.6 (2.4, 5.2) 8.9 (6.8, 11.4) 10.3 (7.9, 13.2) 
 
1.55 (1.20, 1.99) 
 
Previous other stress urinary incontinence 
procedure  
 
      
  No 94710 (99.6)  2.6 (2.5, 2.7) 5.5 (5.4, 5.7) 6.9 (6.7, 7.1) 
 
Reference <0.001 
  Yes 347 (0.4)  7.0 (4.6, 10.0) 12.5 (9.2, 16.3) 14.5 (10.7, 18.8) 
 
2.29 (1.66, 3.14) 
 
Concurrent prolapse repair 
 
 
      
  No 77932 (82.0)  2.6 (2.5, 2.7) 5.6 (5.4, 5.8) 7.0 (6.8, 7.3) 
 
Reference 0.001 
  Repair with mesh 817 (0.9)  4.3 (3.1, 5.9) 7.8 (6.0, 9.8) 9.6 (6.9, 12.8) 
 
1.43 (1.09, 1.87) 
 
  Repair without mesh 16308 (17.2)  2.4 (2.2, 2.7) 5.2 (4.8, 5.6) 6.3 (5.8, 6.8) 
 
0.92 (0.83, 1.01) 
 
Specialist urogynecology unit 
 
 
      
  No 75695 (79.6)  2.5 (2.4, 2.6) 5.5 (5.3, 5.6) 6.8 (6.6, 7.1) 
 
Reference 0.37 
  Yes 19362 (20.4)  3.0 (2.8, 3.2) 5.9 (5.6, 6.3) 7.2 (6.7, 7.7) 
 
1.08 (0.91, 1.29) 
 
Annual volume of mesh sling insertions 
 
 
      
  < 60 28939 (30.3)  2.4 (2.2, 2.6) 5.3 (5.0, 5.6) 6.7 (6.3, 7.1) 
 
Reference 0.4 
  60-119 44228 (46.5)  2.7 (2.5, 2.8) 5.7 (5.5, 6.0) 7.1 (6.8, 7.4) 
 
1.07 (0.96, 1.20) 
 
  ≥120 21990 (23.1)  2.6 (2.4, 2.8) 5.5 (5.2, 5.8) 6.8 (6.4, 7.3) 
 
1.02 (0.86, 1.20) 
 
 513 
1Cumulative incidence function and corresponding 95% confidence interval (95% CI) according to time after initial insertion.  514 
2 Sub-hazard ratios calculated with competing risks regression model (Fine & Gray34) adjusted for all patient and hospital factors in table.  515 
3P value obtained from Wald test 516 
4Ethnicity percentages calculated for non-missing data 517 
5Number of comorbidities derived from Royal College of Surgeons Charlson Comorbidity Index518 
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List of Figures & Legends 520 
 521 
Figure 1: Study cohort selection process of women aged 18 and above who had a first-ever mesh sling insertion in the English National Health 522 
Service 523 
 524 
Figure Legend: Study cohort selection process of women aged 18 years and above who had a first-ever mesh insertion in the English National Health Service 525 
from2006-2015. ICD-10 indicates International Classification of Diseases, version 10. 526 
 527 
 528 
Figure 2: Mesh sling removal, reoperation for stress urinary incontinence and any reoperation according to time after initial mesh insertion in 529 
95,057 women 530 
 531 
Figure Legend: Cumulative incidence of mid-urethral sling removal, reoperation for stress urinary incontinence and any reoperation (mesh removal and/or 532 
reoperation for stress urinary incontinence), with death from any cause as a competing risk. The median time of follow-up was 5.5 years (interquartile range 533 
3.2 and 7.5 years) in women who did not have a mesh sling removal and were alive at the end of follow-up.  534 
 535 
 536 
Figure 3: Mesh sling removal and reoperation for stress urinary incontinence according to time after initial insertion in 95,057 women by route of 537 
insertion 538 
 539 
Figure Legend: Cumulative incidence of mid-urethral sling removal and reoperation for stress urinary incontinence by route of initial mesh insertion with 540 
death from any cause as a competing risk. The median time of follow-up was 5.4 years (interquartile range 3.1 to 7.6 years) in women who had an retropubic 541 
insertion and 5.6 years (interquartile range 3.4 to 7.5 years) in those who had a transobturator insertion. 542 
 543 
Figure 4: Total sling removal with no subsequent mid-urethral sling insertion according to time after initial insertion in 60,194 women who had 544 
mesh sling inserted via retropubic route 545 
 546 
Figure Legend: Cumulative incidence of mid-urethral sling removal surgery without subsequent insertion in 60,194 women who had mid-urethral mesh sling 547 
inserted via retropubic route, with death from any cause as a competing risk. 548 
112,152 women with a first mid-urethral meshtape insertion between 1 April 2006 and 31December 2015
17,095 women excluded*
• Resident outside England: n=510
• No relevant ICD-10 code for stress urinaryincontinence (N39.3): n=12,563
• Private sector: n=5,045
95,057 women included
60,194 women with initialretropubic insertion 34,863 women with initialtransobturator insertion
1,820 women had at leastone removal operation 755 women had at leastone removal operation*1,023 episodes failed on multiple criteria
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